Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Trump orders a fast-track marijuana reschedule to Schedule III—reviving a stalled Biden-era process

Trump orders a fast-track marijuana reschedule to Schedule III—reviving a stalled Biden-era process

Rule Changes

A White House executive order aims to break the logjam at DEA. Early backlash from House Republicans and a cannabis-stock selloff underline how much hinges on the still-formal administrative process—and on CMS/FDA follow-through for CBD.

December 18th, 2025: Trump signs EO: “finish Schedule III”

Overview

Trump's executive order instructing DOJ to fast-track marijuana's move to Schedule III immediately triggered a familiar split. Public health and industry groups cheered the potential research and tax impacts, while House Republicans organized opposition, urging Trump to keep marijuana in Schedule I.

The policy reality hasn't changed yet: rescheduling still requires DEA to complete the on-the-record administrative steps and withstand likely legal challenges.

Investors saw limited near-term payoff in the announcement. Cannabis stocks and a major U.S. cannabis ETF dropped sharply. CMS and FDA face pressure to clarify the promised Medicare/CBD pathway.

Play on this story Voices Debate Predict

Key Indicators

43,000+
Public comments on the proposed Schedule III rule
The proposed rule drew a massive comment record and remains tied up in hearing-stage administrative complexity.
40 + D.C.
Jurisdictions with medical marijuana programs
Federal policy remains out of sync with most of the country’s medical-cannabis reality.
6 million
Registered medical marijuana patients cited by the White House
The order frames rescheduling as a patient-safety and evidence gap problem, not a legalization push.
280E
Tax code penalty tied to Schedule I/II trafficking
Moving marijuana to Schedule III would likely end 280E’s denial of normal business deductions for cannabis operators.
26
House Republicans urging Trump to abandon Schedule III
A Sessions/Harris-led letter warned rescheduling would send the wrong message and increase harms, signaling intra-GOP resistance.
~27%
One-day drop cited for a major U.S. cannabis ETF
Market reaction suggested disappointment that rescheduling still doesn’t equal legalization, banking reform, or immediate consumer-market changes.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

October 1970 December 2025

13 events Latest: December 18th, 2025 · 5 months ago Showing 8 of 13
Tap a bar to jump to that date
  1. Trump signs EO: “finish Schedule III”

    Latest Rule Changes

    Trump orders DOJ to expedite completion of the marijuana rescheduling rulemaking and expands federal research initiatives for marijuana and hemp-derived cannabinoids.

  2. Medicare CBD pilot revealed

    Program

    Administration officials describe a Medicare pilot that would provide hemp-derived CBD at no cost with a doctor’s recommendation.

  3. House Republicans organize opposition, urging Trump not to reschedule marijuana

    Statement

    Rep. Pete Sessions and House Freedom Caucus Chair Andy Harris led a letter signed by 24 additional Republicans urging Trump to keep marijuana in Schedule I and warning rescheduling would worsen public-safety risks.

  4. Cannabis stocks and a major U.S. cannabis ETF tumble after the EO

    Market

    Cannabis equities sold off sharply as investors weighed the limited near-term impact absent a completed DEA rule and broader reforms like banking access.

  5. A new DEA administrator takes over amid rescheduling pressure

    Personnel

    Terrance “Terry” Cole is sworn in as DEA administrator as the cannabis rescheduling case remains unresolved.

  6. HHS recommends Schedule III

    Rule Changes

    HHS formally recommends moving marijuana from Schedule I to Schedule III, spotlighting medical use and research barriers.

  7. Biden orders a marijuana scheduling review

    Statement

    President Biden asks DOJ and HHS to start a scientific review of marijuana scheduling under federal law.

  8. Farm Bill carves hemp out of marijuana

    Rule Changes

    Congress excludes hemp (≤0.3% delta-9 THC) from the CSA definition, igniting a CBD market without a clean FDA pathway.

  9. DEA schedules Epidiolex, a CBD drug

    Rule Changes

    After FDA approval, DEA places Epidiolex (purified CBD) in Schedule V—narrowly, not broadly legalizing CBD.

  10. Federal law locks marijuana into Schedule I

    Rule Changes

    Congress enacts the Controlled Substances Act framework that classifies marijuana as Schedule I for decades.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2018-06 to 2018-09

DEA reschedules a cannabis-derived medicine: Epidiolex (CBD)

FDA approved Epidiolex, a purified cannabidiol drug for rare seizure disorders. DEA then placed it in Schedule V, the least restrictive CSA schedule, emphasizing it was a narrow decision tied to an FDA-approved product.

Then

A single CBD medicine became prescribable nationwide under a controlled-substance framework.

Now

It set a template: FDA approval + rescheduling can work, but doesn’t legalize the broader market.

Why this matters now

Trump’s order leans on the same logic—medical use and controlled pathways—without broad legalization.

1985-1999

Marinol (synthetic THC) moves to Schedule III

Synthetic dronabinol was approved for medical use and later rescheduled, culminating in a federal move from Schedule II to Schedule III for FDA-approved capsule formulations.

Then

Prescription access expanded under looser Schedule III controls than Schedule II.

Now

It sharpened the contradiction: THC medicines can be Schedule III while the plant remains Schedule I.

Why this matters now

Schedule III marijuana would widen that contradiction from a pill to a nationally pervasive state industry.

2013-2018

The Cole Memo whiplash: federal tolerance, then rescission

Obama-era DOJ guidance deprioritized federal enforcement against compliant state marijuana systems. In 2018, Attorney General Jeff Sessions rescinded that guidance, reminding states how fragile executive-era cannabis policy can be.

Then

State markets kept operating, but uncertainty and political risk spiked overnight.

Now

It reinforced that only durable law or regulation—not memos—can stabilize cannabis policy.

Why this matters now

A final Schedule III rule would be harder to reverse than a memo, but still politically contestable.

Sources

(17)